Patents by Inventor Maurice Auclair

Maurice Auclair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5883187
    Abstract: A polymer composition is disclosed comprising (A) a first grafted acrylate rubber substrate having an average rubber phase particle size of from about 0.05 to about 0.2 micron; (B) a second grafted acrylate rubber substrate having an average rubber phase particle size of from about 0.2 to about 2 microns; and (C) a matrix polymer wherein each of the first and second rubber substrates are grafted with (i) a vinyl aromatic monomer; (ii) an unsaturated nitrile monomer; and (iii) optionally a compatible polymerizable comonomer based on the total weight of the grafted rubber substrate wherein at least one of the acrylate rubber substrates is a copolymer of from 83 to 98 percent by weight of an acrylate monomer and from 17 to 2 weight percent of an unsaturated nitrile monomer based on the total weight of the acrylate nitrile monomer copolymer rubber; and wherein the composition has an Izod impact value of at least 80 Joules/meter when tested at 23.degree. C. according to ASTM D-256 using a test specimen of 6.35 cm.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: March 16, 1999
    Assignee: Bayer Antwerpen S.A./N.V.
    Inventors: Moh-Ching Oliver Chang, Richard Maurice Auclair
  • Patent number: 3987042
    Abstract: Phenothiazine derivatives are described of the formula ##SPC1##In which X.sub.1 and X.sub.2, which may be the same or different, are H, R, F, Cl, Br, OR, CN, --COR, CH.sub.3, --S--R, --SOR, --SO.sub.2 R or --SO.sub.2 N(CH.sub.3).sub.2, where R is an alkyl group having from 1 to 4 carbon atoms, and the quinuclidine ring is substituted by the group --(CH.sub.2).sub.x -- in the 2- or 3- position, x being 1 or 2 when said group is substituted in the 2-position and being 0 or 1 when said group is substituted in the 3-position (because of electronic hindrance), and their acid addition and quaternary ammonium salts, have valuable pharmacological properties. In particular, these compounds have anti-histaminic, anti-cholinergic, adrenolytic, neuro-sedative, tranquillizing and/or spasmolytic properties.These compounds are prepared by condensing an appropriate phenothiazine with a quinuclidine derivative of the formula ##SPC2##In which x has the above-stated meaning and Z is a halogen atom or a reactive ester group.
    Type: Grant
    Filed: October 10, 1975
    Date of Patent: October 19, 1976
    Inventors: Claude Gueremy, Robert Labey, Didier Wirth, Maurice Auclair